JW Shinyak said it will resume sales of SK bioscience's influenza vaccine, SKY Cellflu Quardrivalent Prefilled Syringe.

SKY Cellflu Quardrivalent  is a cell-culture influenza vaccine developed by SK bioscience that protects against four types of influenza viruses -- including two types of influenza A viruses and two types of influenza B viruses -- in a single vaccination.

The company had previously signed a joint marketing agreement with SK bioscience for the vaccine in 2016 and has been in charge of sales and marketing activities targeting specialized clinics such as dermatology, urology, and plastic surgery.

However, SK bioscience suspended production of SKYCELL Flu Quadrivalent for the past two years to ensure a smooth supply of SKYCovione, its Covid-19 vaccines.

With the Covid-19 outbreak entering an endemic phase, SK bioscience has resumed production of SKY Cellflu in anticipation of a sharp increase in the incidence of flu this year due to the lifting of social distancing and indoor masks.

With the normalization of the supply of the vaccine, JW Shinyak will resume sales of the flu vaccine and expand its presence in the flu vaccine market based on its own sales and marketing competitiveness.

"Recently, the number of suspected flu patients per 1,000 people has exceeded 15, which is three times the epidemic threshold (4.9) set by the Korea Disease Control and Prevention Agency," a JW Shinyak official said. "We will strive to ensure that the supply of vaccines is not disrupted in time for October, when the incidence of flu usually spikes."